Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE-003: ONC-392 versus docetaxel in metastatic squamous non-small cell lung cancer after PD-1/PD-L1 inhibitor progression
2023-505311-20-01Phase 3Authorised
- Sponsor
- OncoC4
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma comparing ONC-392 with Docetaxel (2 arms). Primary endpoint: Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
gotistobartdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2023-505311-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505311-20-01.